Literature DB >> 6944160

Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14C]-labeled AD 32 administration. Evidence for tissue aglycone formation.

M Israel, A M Karkowsky, V K Khetarpal.   

Abstract

Levels of radioactivity and total anthracycline fluorescence in tissues of A/JAX mice were compared 1 h after IV administration of unlabeled or [14C]-labeled AD 32 (50 mg/kg). Highest levels of both fluorescence and radioactivity were found in the small intestine (including contents) and liver, a result consistent with the known hepatobiliary excretion of AD 32 and metabolites. Significant accumulations of radioactivity and fluorescence were found in kidney, spleen, large intestine (including contents), lung, and heart. Lesser levels were found in muscle and fat. Little radioactivity and fluorescence were found in brain. Liquid chromatographic analysis of extracts of small intestine and liver homogenates showed N-trifluoroacetyladriamycin (AD 41) as the major fluorescent species, and also revealed N-trifluoroacetyladriamycinol (AD 92) and occasional low levels of AD 32. In addition, there was a major peak of nonfluorescent radioactive material and two fluorescent nonradioactive signals (unknowns 1 and 2), indicative of cleavage of the radiolabel from the chromophore.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6944160     DOI: 10.1007/bf00253006

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  N-trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies.

Authors:  L M Parker; M Hirst; M Israel
Journal:  Cancer Treat Rep       Date:  1978-01

2.  Urinary anthracycline metabolites from mice treated with adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Authors:  M Israel; W J Pegg; P M Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1978-03       Impact factor: 4.030

3.  Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog.

Authors:  R H Blum; M B Garnick; M Israel; G P Canellos; I C Henderson; E Frei
Journal:  Cancer Treat Rep       Date:  1979-05

4.  Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate.

Authors:  A Vecchi; M Cairo; A Mantovani; M Sironi; F Spreafico
Journal:  Cancer Treat Rep       Date:  1978-01

5.  Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat.

Authors:  M Israel; P M Wilkinson; W J Pegg; E Frei
Journal:  Cancer Res       Date:  1978-02       Impact factor: 12.701

6.  Pharmacologic studies with radiolabeled N-trifluoroacetyladriamycin-14-valerate (AD 32). Comparison of total anthracycline fluorescence and radioactivity in mouse serum and urine.

Authors:  M Israel; A M Karkowsky; W J Pegg
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

7.  N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.

Authors:  M Israel; E J Modest; E Frei
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

  7 in total
  1 in total

1.  Radioactive species in rat urines and tissues after [14C] AD 32 administration.

Authors:  G Zini; G P Vicario; M Lazzati; F Arcamone
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.